Renal cell cancer: Highlights from ASCO 2020
Prof Scott Tykodi - University of Washington, Seattle, USA
Renal cell cancer: Highlights from ASCO 2020 ( Prof Scott Tykodi - University of Washington, Seattle, USA )
13 Jul 2020
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-re...
Prof Scott Tykodi - University of Washington, Seattle, USA
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advanced renal cell carcinoma ( Prof Scott Tykodi - University of Washington, Seattle, USA )
13 Jul 2020
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer
Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer ( Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA )
10 Jul 2020
The future of PARP inhibitors in prostate cancer
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
The future of PARP inhibitors in prostate cancer ( Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain )
2 Jul 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
30 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )
24 Jun 2020
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2...
Prof Robert Huddart and Dr Ignacio Durán
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 ( Prof Robert Huddart and Dr Ignacio Durán )
15 Jun 2020
CTC count as a prognostic marker for androgen deprivation plus orteronel or bica...
Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA
CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )
12 Jun 2020
Updated results from KEYNOTE-426 for metastatic kidney cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Updated results from KEYNOTE-426 for metastatic kidney cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve p...
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
HCRN GU16-260: Nivolumab and salvage nivolumab   ipilimumab in treatment-naïve patients with advanced renal cell carcinoma ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Comment: JAVELIN-100 for metastatic urothelial cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
PARP inhibitors in prostate cancer: Choices of tests and how to test?
Dr Kim Chi and Dr Alexander Wyatt
PARP inhibitors in prostate cancer: Choices of tests and how to test? ( Dr Kim Chi and Dr Alexander Wyatt )
11 Jun 2020